145 related articles for article (PubMed ID: 33435133)
1.
Voutsadakis IA
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33435133
[TBL] [Abstract][Full Text] [Related]
2. The Landscape of PIK3CA Mutations in Colorectal Cancer.
Voutsadakis IA
Clin Colorectal Cancer; 2021 Sep; 20(3):201-215. PubMed ID: 33744168
[TBL] [Abstract][Full Text] [Related]
3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
4. 3q26 Amplifications in Cervical Squamous Carcinomas.
Voutsadakis IA
Curr Oncol; 2021 Jul; 28(4):2868-2880. PubMed ID: 34436017
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Femi OF
Int J Health Sci (Qassim); 2018; 12(1):28-32. PubMed ID: 29623014
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and biological analysis of
Razia S; Nakayama K; Nakamura K; Ishibashi T; Ishikawa M; Minamoto T; Iida K; Otsuki Y; Nakayama S; Ishikawa N; Kyo S
Exp Ther Med; 2019 Sep; 18(3):2278-2284. PubMed ID: 31410178
[TBL] [Abstract][Full Text] [Related]
7. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
8. The Genomic Environment of
Voutsadakis IA
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079062
[TBL] [Abstract][Full Text] [Related]
9. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China.
Liu J; Li Z; Lu T; Pan J; Li L; Song Y; Hu D; Zhuo Y; Chen Y; Xu Q
BMC Med Genomics; 2022 Nov; 15(1):231. PubMed ID: 36333792
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Miyake T; Yoshino K; Enomoto T; Takata T; Ugaki H; Kim A; Fujiwara K; Miyatake T; Fujita M; Kimura T
Cancer Lett; 2008 Mar; 261(1):120-6. PubMed ID: 18180098
[TBL] [Abstract][Full Text] [Related]
13. The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Spaans VM; Nyoman Bayu Mahendra I; Purwoto G; Trietsch MD; Osse M; Ter Haar N; Peters AAW; Fleuren GJ; Jordanova ES
Gynecol Oncol; 2018 Jan; 148(1):189-196. PubMed ID: 29113722
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenesis of PIK3CA.
German S; Aslam HM; Saleem S; Raees A; Anum T; Alvi AA; Haseeb A
Hered Cancer Clin Pract; 2013 Jun; 11(1):5. PubMed ID: 23768168
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
16.
Tang Y; Li J; Xie N; Yang X; Liu L; Wu H; Tian C; He Y; Wang X; He Q; Hu ZY; Ouyang Q
Aging (Albany NY); 2020 Jan; 12(2):1577-1590. PubMed ID: 31980592
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
[TBL] [Abstract][Full Text] [Related]
20. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
